Evaluation of EXL01, a New Live Biotherapeutic Product to Prevent Recurrence of Clostridioides Difficile Infection in High-risk Patients
Latest Information Update: 20 Apr 2025
At a glance
- Drugs EXL-01 (Primary)
- Indications Clostridium difficile infections
- Focus Adverse reactions; Therapeutic Use
Most Recent Events
- 14 May 2024 Planned End Date changed from 1 Jan 2027 to 7 Jan 2027.
- 14 May 2024 Planned primary completion date changed from 1 Jan 2027 to 7 Jan 2027.
- 14 May 2024 Status changed from not yet recruiting to recruiting.